Sort
15,842 grants matching “pancreatic cancer”
Functional Evaluation of Human Pancreatic Cancer Genes in a Zebrafish System
$300,591Steven D Leach · Johns Hopkins University · P01 · FY2010 · CA
Functional Evaluation of microRNAs in Pancreatic Neoplasia
$300,533Joshua T Mendell · Johns Hopkins University · P01 · FY2010 · CA
Research Testbed 1
$300,529Paolo Provenzano · University Of Minnesota · U54 · FY2025 · CA
The Hippo Signaling Pathway in Pancreatic Cancer
$300,518Anirban Maitra · Johns Hopkins University · P01 · FY2010 · CA
Investigating the cause of racial/ethnic disparity in pancreatic cancer incidence
$300,442Veronica Wendy Setiawan · University Of Southern California · R01 · FY2020 · CA
Discovery and Evaluation of Prioritized Mutations in Pancreatic Cancer
$300,431Scott E Kern · Johns Hopkins University · P01 · FY2010 · CA
Zinc enrichment/zinc sensing mechanism through the extracellular domain of ZIP4
$300,415Jian Hu · Michigan State University · R01 · FY2019 · GM
Zinc enrichment/zinc sensing mechanism through the extracellular domain of ZIP4
$300,415Jian Hu · Michigan State University · R01 · FY2018 · GM
The Role of p16INK4a in Mammalian Aging
$300,366Norman Edward Sharpless · Univ Of North Carolina Chapel Hill · R01 · FY2010 · AG
Wnt/beta-catenin signaling in exocrine pancreas developoment and regeneration
$300,346Lewis C Murtaugh · University Of Utah · R01 · FY2008 · DK
Wnt/beta-catenin signaling in exocrine pancreas developoment and regeneration
$300,346Lewis C Murtaugh · University Of Utah · R01 · FY2009 · DK
Enhancing immune therapy in pancreatic cancer by targeting IL-6
$300,300Gregory B. Lesinski · Emory University · R01 · FY2016 · CA
Kras-Induced Cellular Plasticity in Pancreatic Cancer
$300,006Stephen F Konieczny · Purdue University · R01 · FY2012 · CA
T-32 NIH Postdoctoral Training Program in Nanotechnology for Cancer Medicine NTCM
$300,003Denis Wirtz · Johns Hopkins University · T32 · FY2012 · CA
A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates
$300,000Herbert Wanjala Kavunja · Iaso Therapeutics, Inc. · R43 · FY2020 · CA
Role of Neuropillins in Pancreatic Cancer
$300,000Murray Korc · Dartmouth College · R01 · FY2007 · CA
North Central Cancer Treatment Group
$300,000Jan C Buckner · Mayo Clinic Rochester · U10 · FY2007 · CA
Oral formulation for novel inhibitor of Ras driven cancers
$300,000Joshua Canzoneri · Adt Pharmaceuticals, Llc · R43 · FY2017 · CA
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
$300,000Gail E Sonenshein · Adecto Pharmaceuticals, Inc. · R41 · FY2016 · CA
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
$300,000Ward Peterson · Symberix, Inc. · R44 · FY2018 · CA
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** PANCREATIC CANCER IS OFTEN DIAGNOSED AT AN ADVANCED STAGE AND IT IS HIGHLY RESISTANT TO CONVENTIONAL CHEMOTHERAPY AND RADIATION THERAPY WHICH MAKES IT DIFFICULT TO TREAT. THE PROGRESSION FROM NORMAL PANCREATIC EPITHELIUM TO PANCREATIC CANCER IS ASSOCIATED WITH THE ACCUMULATION OF SEVERAL GENETIC MUTATIONS AND GRADUALLY EVOLVES VIA PRECURSOR LESIONS, CALLED PANCREATIC INTRAEPITHELIAL NEOPLASIA (PANIN) LESIONS. EPIDEMIOLOGICAL STUDIES HAVE SUGGESTED THAT CONSUMPTION OF CRUCIFEROUS VEGETABLES IS ASSOCIATED WITH A LOWER RISK OF DEVELOPING CANCERS, INCLUDING PANCREATIC CANCER.THE OVERARCHING GOAL OF THIS PROJECT IS TO CHARACTERIZE THE EFFICACY OF ORAL ADMINISTRATION OF THE CRUCIFEROUS VEGETABLE WATERCRESS (NASTURTIUM OFFICINALE) ON PREVENTING THE DEVELOPMENT AND PROGRESSION OF EARLY LESIONS OF PANCREATIC INTRAEPITHELIAL NEOPLASIA TO MORE ADVANCED LESIONS AND PANCREATIC CANCER, AND ON MODULATING THE GUT MICROBIOME. THE SPECIFIC AIMS OF THIS PROJECT ARE (1) TO DETERMINE THE EFFICACY OF FREEZE-DRIED WATERCRESS ON PREVENTING THE DEVELOPMENT AND PROGRESSION OF PRECURSOR PANIN LESIONS TO INVASIVE PANCREATIC ADENOCARCINOMA, BY USING A TRANSGENIC ANIMAL MODEL WHICH RESEMBLES HISTOPATHOLOGICAL FEATURES OF THE HUMAN DISEASE, AND (2) TO CHARACTERIZE THE EFFECT OF FREEZE-DRIED WATERCRESS CONSUMPTION ON THE GUT MICROBIOME USING METAGENOMICS SEQUENCING.THIS STUDY WILL PROVIDE INFORMATION REGARDING BIOMARKERS OF RESPONSE TO FREEZE-DRIED WATERCRESS IN A PANCREATIC CANCER MODEL. THE LONG-TERM GOAL IS TO DEVELOP A STRATEGY TO PREVENT THE PROGRESSION OF PANIN LESIONS TO PANCREATIC CANCER USING A WHOLE-FOOD APPROACH.
$300,000Board Of Regents Of Nevada System Of Higher Education · · FY2023 · National Institute of Food and Agriculture
Novel Ras inhibitor prodrug for colorectal cancer
$300,000Joshua Canzoneri · Adt Pharmaceuticals, Llc · R43 · FY2016 · CA
Development of Inhibitors of cANGPTL4 for Pancreatic Cancer Therapeutics
$300,000Aj Singhal · Cfd Research Corporation · R43 · FY2019 · CA
A Unique Deployable Thermosensor Probe for the Minimally Invasive Treatment of Renal Tumors
$300,000Kristi K Snyder · Cell Preservation Services, Inc. · R43 · FY2018 · CA
Robust Predictor of Colon Cancer Risk
$300,000Harry Ostrer · Morgan And Mendel Genomics, Inc. · R41 · FY2018 · CA